Canada: Supreme Court Of Canada Establishes Important Principles In Transfer Pricing

Last Updated: December 10 2012
Article by Claire M.C. Kennedy, Martin P.J. Kratz and Darrel Pearson

The Supreme Court of Canada recently released its judgment in The Queen v Glaxo Smith Kline Inc., (Glaxo),1 which is the Court's first pronouncement on Canada's transfer pricing rules. Transfer pricing involves the allocation of profits in cross-border transactions among related parties and it is a contentious issue that can result in double taxation for taxpayers as governments in different jurisdictions seek to tax the same income. Transfer pricing is a high priority enforcement area for the Canada Revenue Agency and revenue authorities in other countries. Although the Glaxo case involved the interpretation of an earlier iteration of Canada's transfer pricing rules, the Supreme Court's reasons establish some key principles that should have application to Canada's current transfer pricing regime and the case is therefore an important one for Canadian multi-nationals. Overall, the decision is a positive one for Canadian businesses; however, the Supreme Court has sent a clear signal that allocation of transfer prices among related parties participating in multiple transactions, such as the licence of a trademark and the supply of goods and/or services, will be carefully scrutinized. Multiple transaction arrangements are common amongst multi-national enterprises large and small and, in light of the Glaxo case, businesses should revisit their transfer pricing documentation and legal agreements to mitigate the risk of reassessment and penalties by tax and customs authorities.

At issue in Glaxo were the prices paid by Glaxo Canada, the Canadian member of the Glaxo pharmaceutical group, to a related Swiss entity, Adechsa, for purchases of the active ingredient in the anti-ulcer drug, Zantac, during the period 1990-1993. The fact that the case involves events that occurred more than 20 years ago speaks to the burdens of tax compliance in transfer pricing and the need for taxpayers to maintain excellent records.

Glaxo Canada was a so-called secondary manufacturer and marketer of Zantac in Canada. In other words, it purchased the active raw ingredient (ranitidine), assembled it with other ingredients into pill form, and sold the finished brand name drug. Glaxo Canada did not own the patent for ranitidine; it did not conduct its own R&D on this drug and it did not own the trademark Zantac.

Glaxo Canada obtained essential inputs for its business from related parties. In particular, it entered into a Licence Agreement with a U.K. affiliate (Glaxo Group) that gave Glaxo Canada the rights under relevant patents to manufacture, use and sell Glaxo Group products, including Zantac, exclusive rights to Glaxo Group trademarks, including Zantac, and related technical and marketing support and services. It was a condition of the Licence Agreement that Glaxo Canada purchase ranitidine from a supplier approved by Glaxo Group. At the time, there were two such suppliers, both of which were Glaxo affiliates, and Glaxo Canada entered into a Supply Agreement with one of them (Adechsa).

Under the Licence Agreement, Glaxo Canada paid Glaxo Group a six-percent royalty. The Supply Agreement provided for a formula price for ranitidine that would yield a 60-percent gross margin to Glaxo Canada after taking into account the royalty. This formula resulted in a price per kg of ranitidine exceeding $1500. At that time, generic drug manufacturers were purchasing ranitidine from non-Glaxo sources for approximately $300/kg. The Canadian revenue authority reassessed Glaxo Canada on the basis that the purchase price paid to Adechsa was excessive and exceeded a "reasonable amount", which is the functional equivalent of the "arm's length standard" in the modern wording of the transfer pricing rules, which were rewritten in 1998 after the events of this case.

Zantac, the brand name drug, commanded a significant price premium in the market compared to the equivalent generic products. Nonetheless, the government argued that the Licence Agreement, which gave Glaxo Canada the right to use the brand name Zantac, was irrelevant and that the Licence Agreement transactions and Supply Agreement transactions had to be evaluated independently. Accordingly, the government concluded the generic suppliers' purchases of ranitidine represented comparable arm's length transactions and their price (approximately $300/kg) represented the "comparable uncontrolled price" or CUP that was reasonable in the circumstances.

The government's position was rejected by the Supreme Court of Canada. The Court held that the Licence Agreement added value to the Adechsa-sourced ranitidine over and above the value of generic ranitidine without the associated rights and benefits and could not be ignored.2 The Court therefore rejected a strict transaction-by-transaction approach recognizing that it is necessary to consider "economically relevant characteristics" in applying transfer pricing principles, especially alleged arm's length comparables.

Importantly for taxpayers, the Court also acknowledged that "transfer pricing is not an exact science" and "some leeway must be allowed in the determination of reasonable amount" so that "as long as a transfer price is within what a court determines is a reasonable range, the requirement of [the transfer pricing provisions] should be satisfied." 3

The Supreme Court's finding that the Licence Agreement was relevant to the determination of the purchase price paid under the Supply Agreement was fatal to the government's position that the generic price was the transfer price that Glaxo Canada should have used. The Court observed that considering the Licence and Supply Agreements together gave a "realistic picture" of Glaxo Canada's profits and noted the limited functions and risks of Glaxo Canada as a secondary manufacturer that did not originate new products and the related intellectual property.4

However, the Court also observed that the prices Glaxo Canada paid to Adechsa were a payment for both the raw ingredient under the Supply Agreement and a bundle of at least some rights and benefits under the Licence Agreement and correctly identified that the allocation could have Canadian withholding tax implications. (Royalties paid by a Canadian entity to a non-resident for the use of intellectual property are generally subject to Part XIII withholding tax but the purchase price for goods is not. Moreover, transfer pricing rules also apply for customs purposes and certain royalties paid in respect of imported goods are dutiable while others are not, and the quantum of royalties is one factor impacting dutiability.)

The Supreme Court referred the Glaxo case back to the Tax Court of Canada for a determination of the proper transfer price for ranitidine paid by Glaxo Canada, so we may not have heard the final word on this case.

Nonetheless, the Glaxo decision is immediately relevant to Canadian businesses transacting with affiliates in other countries. On the plus side, businesses can take comfort in the Supreme Court's recognition that transfer pricing is not an exact science and that some deference should be accorded to taxpayers in making transfer pricing evaluations. Moreover, the Court's insistence on considering all the economically relevant characteristics of the government's alleged CUP and rejecting the government's transaction-by-transaction approach, which did not yield a realistic picture of Canadian profits, establishes a common sense approach to what can be an arcane area.

The Supreme Court's careful scrutiny of elements of the Licence Agreement and observation that a taxpayer's allocation of transfer prices could have withholding tax implications is a clear signal that courts (and by extension the tax authorities) will carefully examine all the relevant elements of the relationship among cross-border related parties. We note that such allocation will have often overlooked ramifications for customs transfer pricing, which should be taken into account by businesses to achieve a unified approach to tax and customs transfer pricing.

Post-Glaxo, taxpayers should revisit their transfer pricing practices and ensure their transfer pricing documentation is adequate by:

  • verifying the validity of the comparables cited in their transfer pricing study and
  • ensuring that their legal agreements accurately, and in sufficient detail, identify all the related party transfers of services, goods and intellectual property.


1 2012 SCC 52

2 Paragraph 60 of the Reasons

3 Paragraph 61 of the Reasons

4 Paragraph 51 of the Reasons

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

Claire M.C. Kennedy
Martin P.J. Kratz
Darrel Pearson
In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions